Clinical Trials Browser

Leukemia, Large Granular Lymphocytic

NCT01125176 2022-01-21

ThRiL

Phase 2 Completed

15 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00274820 2020-07-27

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Phase 2 Completed

15 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03980002 2019-06-10

BDHCLL001

Phase 2 Recruiting

50 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Phase 2 Completed

101 enrolled 10 charts

CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

NCT00006226 2013-10-08

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase 2 Completed

41 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00009984 2013-06-06

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Phase 2 Terminated

70 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00030550 2013-01-31

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Phase 2 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00015990 2013-01-24

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Phase 2 Completed

29 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

NCT00022581 2013-01-07

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

45 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00083694 2010-07-02

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Phase 2 Completed

25 enrolled

Other hematologic neoplasm

Leukemia, Recurrence

NCT00053287 2010-06-10

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Phase 2 Completed

42 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Clinical Trials

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

ThRiL

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

BDHCLL001

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS